Coya Therapeutics Inc

Coya Therapeutics Inc a clinicalstage biotechnology company develops proprietary medicinal products to modulate the function of regulatory T cells Tregs The companys product candidate pipeline is based on therapeutic modalities such as Tregenhancing biologics Tregderived exosomes and autologous Treg cell therapy It is developing COYA 101 an autologous regulatory Tcell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis The companys product candidates in INDenabling studies include COYA 301 a Tregenhancing biologic for use in the treatment of Frontotemporal Dementia and COYA 302 a biologic combination for subcutaneous andor intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases It is also developing COYA 201 an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative autoimmune and metabolic diseases and COYA 206 an antigen directed Tregderived exosome product candidate which is in discovery stage The company was incorporated in 2020 and is headquartered in Houston Texas